Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.55 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.49 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.49 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5657330 | 0.84 | CARM1 (0.48) | SIGMAR1CARM1PRMT6 | |
| SCHEMBL1283169 | 0.82 | AGER (0.45) | SIGMAR1HRH3 | |
| SCHEMBL751432 | 0.81 | PARP15 (0.50) | SIGMAR1 | |
| SCHEMBL3989257 | 0.78 | PARP15 (0.53) | SIGMAR1 | |
| SCHEMBL3575584 | 0.78 | PARP15 (0.53) | SIGMAR1 | |
| SCHEMBL5655460 | 0.78 | CYP4F2 (0.52) | SIGMAR1 | |
| SCHEMBL9815661 | 0.78 | PARP15 (0.41) | SIGMAR1 | |
| SCHEMBL9815659 | 0.78 | PARP15 (0.41) | SIGMAR1 | |
| SCHEMBL5657345 | 0.78 | HRH3 (0.68) | CARM1PRMT6HRH3 | |
| SCHEMBL1987414 | 0.76 | PARP10 (0.54) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7279498-B2 | Substituted aryl amides as IP antagonists | ROCHE PALO ALTO LLC (US) | 2007-10-09 | — | — | US | disclosed |
| US-6998414-B2 | Substituted arylamides as IP antagonists | ROCHE PALO ALTO LLC (US) | 2006-02-14 | — | — | US | disclosed |
| EP-1622611-A1 | IMIDAZOLIN-2-YLAMINOPHENYL AMIDES AS IP ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-02-08 | — | — | EP | disclosed |
| US-20060004075-A1 | Substituted aryl amides as IP antagonists | ROCHE PALO ALTO LLC | 2006-01-05 | — | — | US | disclosed |
| WO-2004096213-A1 | IMIDAZOLIN-2-YLAMINOPHENYL AMIDES AS IP ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-11-11 | — | — | WO | disclosed |
| US-20040220247-A1 | Substituted arylamides as IP antagonists | ROCHE PALO ALTO LLC | 2004-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060004075-A1 | Substituted aryl amides as IP antagonists | INSR, INSRR, GIPR | SIGMAR1 17/4885CARM1 1591/4885PRMT6 2270/4885 |
| US-20040220247-A1 | Substituted arylamides as IP antagonists | INSR, PTGER1, INSRR | SIGMAR1 13/4885CARM1 1874/4885PRMT6 2846/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.